Allergan (NYSE:AGN) issued its earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, topping the consensus estimate of $4.74 by $0.12, Bloomberg Earnings reports. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. The business had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.28 billion. During the same period last year, the company posted $3.90 EPS. The business’s quarterly revenue was up 12.0% on a year-over-year basis. Allergan updated its Q1 guidance to $3.20-3.40 EPS and its FY18 guidance to $15.25-16.00 EPS.
Allergan (NYSE AGN) traded down $2.31 on Tuesday, hitting $160.15. The stock had a trading volume of 1,015,850 shares, compared to its average volume of 3,032,534. The company has a market capitalization of $54,030.00, a PE ratio of -13.36, a PEG ratio of 1.17 and a beta of 1.19. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.88 and a current ratio of 2.04. Allergan has a 52 week low of $156.11 and a 52 week high of $256.80.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.80%. The ex-dividend date is Tuesday, February 27th. This is a boost from Allergan’s previous quarterly dividend of $0.70. Allergan’s payout ratio is -23.35%.
Several research firms have commented on AGN. JPMorgan Chase & Co. reissued a “buy” rating and issued a $275.00 price objective on shares of Allergan in a research report on Monday, October 16th. Zacks Investment Research lowered Allergan from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Deutsche Bank set a $251.00 target price on Allergan and gave the stock a “buy” rating in a research report on Tuesday, October 17th. UBS Group set a $255.00 target price on Allergan and gave the stock a “buy” rating in a research report on Tuesday, October 17th. Finally, Credit Suisse Group set a $243.00 target price on Allergan and gave the stock an “outperform” rating in a research report on Tuesday, October 17th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $227.23.
In other news, insider William Meury sold 11,807 shares of Allergan stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $173.89, for a total transaction of $2,053,119.23. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Christopher J. Coughlin purchased 10,000 shares of the business’s stock in a transaction dated Tuesday, December 5th. The shares were acquired at an average cost of $163.30 per share, for a total transaction of $1,633,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 17,630 shares of company stock worth $2,890,057. Corporate insiders own 0.36% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Cable Hill Partners LLC raised its holdings in Allergan by 255.2% during the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after purchasing an additional 370 shares in the last quarter. Rockefeller Financial Services Inc. raised its holdings in Allergan by 283.7% during the third quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock worth $111,000 after purchasing an additional 400 shares in the last quarter. Phocas Financial Corp. bought a new stake in Allergan during the second quarter worth approximately $150,000. BB&T Investment Services Inc. raised its holdings in Allergan by 1,308.2% during the third quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock worth $139,000 after purchasing an additional 641 shares in the last quarter. Finally, WFG Advisors LP raised its holdings in Allergan by 20.9% during the second quarter. WFG Advisors LP now owns 793 shares of the company’s stock worth $193,000 after purchasing an additional 137 shares in the last quarter. 79.76% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/13/allergan-agn-announces-earnings-results-beats-expectations-by-0-12-eps.html.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.